Credit Suisse’s Amphastar Pharmaceuticals AMPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $2.25M | Hold |
51,312
| – | – | ﹤0.01% | 1771 |
|
|
2023
Q4 | $3.17M | Sell |
51,312
-175
| -0.3% | -$9.19K | ﹤0.01% | 1611 |
|
|
2023
Q3 | $2.37M | Buy |
51,487
+302
| +0.6% | +$16.5K | ﹤0.01% | 1722 |
|
|
2023
Q2 | $2.94M | Sell |
51,185
-6,771
| -12% | -$300K | ﹤0.01% | 1671 |
|
|
2023
Q1 | $2.17M | Buy |
57,956
+2,246
| +4% | +$73.6K | ﹤0.01% | 1813 |
|
|
2022
Q4 | $1.56M | Buy |
55,710
+16,781
| +43% | +$487K | ﹤0.01% | 2027 |
|
|
2022
Q3 | $1.09M | Buy |
38,929
+3,531
| +10% | +$115K | ﹤0.01% | 2266 |
|
|
2022
Q2 | $1.23M | Sell |
35,398
-6,137
| -15% | -$219K | ﹤0.01% | 2242 |
|
|
2022
Q1 | $1.49M | Buy |
41,535
+5,465
| +15% | +$155K | ﹤0.01% | 2277 |
|
|
2021
Q4 | $840K | Buy |
36,070
+1,403
| +4% | +$28.7K | ﹤0.01% | 3453 |
|
|
2021
Q3 | $659K | Sell |
34,667
-4,407
| -11% | -$86.3K | ﹤0.01% | 3632 |
|
|
2021
Q2 | $787K | Sell |
39,074
-2,427
| -6% | -$45.7K | ﹤0.01% | 3558 |
|
|
2021
Q1 | $760K | Sell |
41,501
-9,010
| -18% | -$168K | ﹤0.01% | 3494 |
|
|
2020
Q4 | $1.02M | Buy |
50,511
+12,109
| +32% | +$236K | ﹤0.01% | 3335 |
|
|
2020
Q3 | $719K | Sell |
38,402
-1,717
| -4% | -$34.6K | ﹤0.01% | 3158 |
|
|
2020
Q2 | $901K | Buy |
40,119
+5,804
| +17% | +$106K | ﹤0.01% | 2967 |
|
|
2020
Q1 | $509K | Sell |
34,315
-4,027
| -11% | -$70.1K | ﹤0.01% | 3102 |
|
|
2019
Q4 | $739K | Sell |
38,342
-636
| -2% | -$12.2K | ﹤0.01% | 3328 |
|
|
2019
Q3 | $772K | Buy |
38,978
+9,306
| +31% | +$194K | ﹤0.01% | 3186 |
|
|
2019
Q2 | $627K | Sell |
29,672
-8,452
| -22% | -$177K | ﹤0.01% | 3267 |
|
|
2019
Q1 | $780K | Sell |
38,124
-9,759
| -20% | -$219K | ﹤0.01% | 3078 |
|
|
2018
Q4 | $953K | Buy |
47,883
+12,752
| +36% | +$251K | ﹤0.01% | 2808 |
|
|
2018
Q3 | $677K | Sell |
35,131
-12,713
| -27% | -$227K | ﹤0.01% | 3118 |
|
|
2018
Q2 | $729K | Sell |
47,844
-3,264
| -6% | -$57K | ﹤0.01% | 3234 |
|
|
2018
Q1 | $958K | Buy |
51,108
+1,977
| +4% | +$37.2K | ﹤0.01% | 2986 |
|
|
2017
Q4 | $946K | Buy |
49,131
+2,836
| +6% | +$53K | ﹤0.01% | 3033 |
|
|
2017
Q3 | $828K | Buy |
46,295
+23,598
| +104% | +$388K | ﹤0.01% | 3233 |
|
|
2017
Q2 | $405K | Sell |
22,697
-10,724
| -32% | -$170K | ﹤0.01% | 3285 |
|
|
2017
Q1 | $485K | Sell |
33,421
-42,234
| -56% | -$664K | ﹤0.01% | 3304 |
|
|
2016
Q4 | $1.39M | Sell |
75,655
-39,593
| -34% | -$770K | ﹤0.01% | 2737 |
|
|
2016
Q3 | $2.19M | Buy |
115,248
+48,336
| +72% | +$877K | ﹤0.01% | 2308 |
|
|
2016
Q2 | $1.08M | Buy |
66,912
+35,754
| +115% | +$504K | ﹤0.01% | 2856 |
|
|
2016
Q1 | $374K | Buy |
31,158
+3,755
| +14% | +$44.3K | ﹤0.01% | 3401 |
|
|
2015
Q4 | $391K | Sell |
27,403
-21,880
| -44% | -$289K | ﹤0.01% | 3539 |
|
|
2015
Q3 | $576K | Sell |
49,283
-22,342
| -31% | -$335K | ﹤0.01% | 3292 |
|
|
2015
Q2 | $1.26M | Buy |
71,625
+22,709
| +46% | +$354K | ﹤0.01% | 2960 |
|
|
2015
Q1 | $732K | Buy |
48,916
+31,110
| +175% | +$416K | ﹤0.01% | 3246 |
|
|
2014
Q4 | $206K | Buy |
+17,806
| New | +$194K | ﹤0.01% | 4259 |
|
Other funds holding AMPH
EIP
Credit Suisse's AMPH Position: Q1 2024 in Review
Credit Suisse held its Amphastar Pharmaceuticals (AMPH) position steady in Q1 2024 at 51,312 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1771.
Credit Suisse first reported a position in AMPH in Q4 2014 and has held it in 38 quarters since. The position peaked at $3.17M in Q4 2023. 271 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.
- Credit Suisse held 51,312 shares of Amphastar Pharmaceuticals worth $2.25M as of Q1 2024.
- Credit Suisse left its Amphastar Pharmaceuticals share count unchanged in Q1 2024.
- Amphastar Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1771 holding.
- Credit Suisse first reported a position in Amphastar Pharmaceuticals in Q4 2014 and has held it in 38 quarters since.
- Credit Suisse's Amphastar Pharmaceuticals position peaked at $3.17M in Q4 2023.
- 271 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.